ECO Animal Health Group (LSE:EAH), the animal health company focused on livestock, has submitted a Marketing authorisation application in Europe for its second poultry vaccine, days after warning that Revenue for the current year would fall short of market forecasts because of weaker sales in China and Japan. Both announcements were made in November 2026, alongside a Capital Markets day, and highlight a Business trying to diversify its product base.

What the company does

ECO Animal Health develops and sells medicines and vaccines for farm animals, with poultry an important market. Its established product is Aivlosin, an antibiotic used in livestock, and it is now building a range of poultry vaccines under the ECOVAXXIN brand. The group sells across several international regions, including Asia, where China and Japan have historically been significant markets.

Latest developments

On 11 November 2026 the company announced that it had submitted a marketing authorisation application to the European Medicines Agency for ECOVAXXIN MG, a live Vaccine against Mycoplasma gallisepticum, a respiratory disease in poultry. It is the second vaccine from the company's pipeline, following ECOVAXXIN MS, which launched commercially in the European Union in July 2026. ECO said it was also pursuing authorisation for the MG vaccine in the United States. In September 2026, it reported that the US regulator's veterinary Biologics centre had approved field safety data for ECOVAXXIN MS.

In August 2026 ECO announced an exclusive in-licensing agreement with Vaxinano, and in September it appointed Didier Branellec as a non-executive director. The company also held a capital markets day on 11 November.

Financial and Dividend picture

The trading update published on 6 November 2026 covered the six months to 30 September 2026. Group revenue fell to £33.0m from £39.0m in the same period of 2025, but gross Margin improved to about 52% from 49.6%, and adjusted EBITDA was broadly flat at around £3.0m. Cash stood at £24m at the end of September.

The regional picture was uneven. Revenue excluding China rose 6%, and sales in South and South East Asia grew by more than half, but revenue in China and Japan declined materially. The board now expects China and Japan revenue for the full year to be less than half of the previous year's level, and group revenue to fall short of market consensus of £89.6m. It expects adjusted EBITDA and Earnings Per Share to be broadly in line with consensus figures of £8.5m and 3.30p respectively. The summary reviewed did not include dividend details.

Sector and index context

ECO is one of the few specialist animal health companies in the FTSE AIM All Share Index. Global Demand for animal protein supports Long-term Growth in livestock medicines, but the sector faces growing regulatory pressure on antibiotic use in farming, which has encouraged a shift towards vaccines and other preventative products. Regulatory approvals for new veterinary products can take several years.

Key risks

The decline in China and Japan shows the company's exposure to individual markets, where pricing, competition and regulation can change quickly. Successful commercialisation of the ECOVAXXIN vaccines is important to offset pressure on established products, and regulatory decisions in Europe and the United States are not assured or within the company's control. Currency movements can also affect reported results.

What to watch next

Interim results for the six months to 30 September 2026 will provide fuller detail on trading and the outlook. Investors will be watching early sales of ECOVAXXIN MS in Europe, progress on the MG application with the European Medicines Agency, the US authorisation process and whether growth in South and South East Asia continues to offset weakness elsewhere.